Could CEA testing be useful for pancreatic cancer patients

CEA Testing for Pancreatic Cancer

Based on the NCCN Guidelines for Patients: Pancreatic Cancer, 2023, CEA (carcinoembryonic antigen) testing is not mentioned as a standard or recommended test for pancreatic cancer patients.

What the Guidelines Recommend Instead

For pancreatic cancer, the guidelines specifically recommend CA 19-9 testing as the primary tumor marker, not CEA. Here's what you should know:

CA 19-9: The Standard Tumor Marker

According to the NCCN Guidelines, CA 19-9 (carbohydrate antigen 19-9) is the blood test used for pancreatic cancer because:

• Pancreatic cancer cells make this specific protein
• High CA 19-9 levels often indicate a higher cancer stage
• It helps your care team plan treatment
• It can be repeated after treatment to check if levels are dropping or rising

Important Limitations

The guidelines note that CA 19-9 cannot be used alone for diagnosis because:

1. High levels can be caused by other conditions, including a blocked bile duct
2. Some people with pancreatic cancer have normal CA 19-9 levels

Also, blood samples must be drawn only when bile ducts are clear, as blocked ducts can affect test results.

Why This Matters

CEA is more commonly used for colorectal cancer monitoring. While some pancreatic cancer patients might have CEA testing done (especially if there's concern about other cancers), it's not part of the standard pancreatic cancer testing protocol outlined in these guidelines.

Bottom line: If you're wondering about tumor marker testing, ask your care team specifically about CA 19-9 levels and what they mean for your situation, as this is the evidence-based marker for pancreatic cancer according to NCCN Guidelines.